NRX PHARMACEUTICALS INC (NRXP)
US6294442099 - Common Stock
NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024
NRXP stock results show that NRX Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips NRX Pharmaceuticals (NASDAQ:NRXP) just reported results for the first quarter o...
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update
2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity...
NRx Pharmaceuticals eyes first commercial revenue in 2024, announces breakthroughs in bi-annual milestone update
Michigan, United States, April 29th, 2024, FinanceWire NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and […]
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024
/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced...
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024
/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced...
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that...
These stocks are moving in today's pre-market session
Get insights into the top gainers and losers of Wednesday's pre-market session.
Tuesday's after hours session: top gainers and losers
Which stocks are moving after the closing bell on Tuesday?
What's going on in today's session
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Which stocks are moving on Tuesday?
Which stocks are experiencing notable movement on Tuesday?
Which stocks are gapping on Tuesday?
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
NRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant at this sample size) and 75%...
Why Is Bio-Path (BPTH) Stock Up 89% Today?
Bio-Path stock is up with heavy trading of BPTH shares today alongside positive news from its ongoing clinical trial of BP1002.
Why Is AGBA Group (AGBA) Stock Up 149% Today?
AGBA Group stock is rising higher on Thursday after the company announced plans to combine with Triller to create a $4 billion entity.
Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?
NRX Pharmaceuticals stock is down on Thursday after the company announced a public offering for NRXP shares after just avoiding delisting.
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today...
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Thursday morning!
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced...
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Friday is here and we're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers this morning!
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced...
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend -- 50% reduction in corporate...
NRXP Stock Earnings: NRX Pharmaceuticals Beats EPS for Q4 2023
NRXP stock results show that NRX Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
NRXP Stock Earnings: NRX Pharmaceuticals Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips NRX Pharmaceuticals (NASDAQ:NRXP) just reported results for the fourth quarter ...